These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 14533492)

  • 21. Hormone replacement therapy in breast cancer patients and survivors.
    Del Priore G; Hatami M
    Curr Womens Health Rep; 2003 Apr; 3(2):165-9. PubMed ID: 12628087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence.
    Verkooijen HM; Bouchardy C; Vinh-Hung V; Rapiti E; Hartman M
    Maturitas; 2009 Oct; 64(2):80-5. PubMed ID: 19709827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormones and breast cancer.
    ESHRE Capri Workshop Group
    Hum Reprod Update; 2004; 10(4):281-93. PubMed ID: 15192054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
    Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
    Chang SC; Lacey JV; Brinton LA; Hartge P; Adams K; Mouw T; Carroll L; Hollenbeck A; Schatzkin A; Leitzmann MF
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
    Bernstein L
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
    Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hormone replacement therapy and the risk of breast cancer].
    Hackmon R; Piura B; Mazor M
    Harefuah; 2002 Mar; 141(3):283-6, 313. PubMed ID: 11944224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone replacement therapy and breast cancer risk in California.
    Coombs NJ; Taylor R; Wilcken N; Fiorica J; Boyages J
    Breast J; 2005; 11(6):410-5. PubMed ID: 16297085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benefits and risks in hormone substitute therapy in postmenopause].
    Baljić T
    Srp Arh Celok Lek; 1996; 124(5-6):143-6. PubMed ID: 9102835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C; Reeves G
    Lakartidningen; 2005 Apr 18-24; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase.
    Espié M; Daures JP; Chevallier T; Mares P; Micheletti MC; De Reilhac P
    Gynecol Endocrinol; 2007 Jul; 23(7):391-7. PubMed ID: 17701770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of breast cancer linked to menopausal hormone therapy.
    Sæther S; Bakken K; Lund E
    Tidsskr Nor Laegeforen; 2012 Jun; 132(11):1330-4. PubMed ID: 22717857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast response to menopausal hormone therapy--aspects on proliferation, apoptosis and mammographic density.
    Conner P
    Ann Med; 2007; 39(1):28-41. PubMed ID: 17364449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HRT and breast cancer: impact on population risk and incidence.
    Coombs NJ; Taylor R; Wilcken N; Boyages J
    Eur J Cancer; 2005 Aug; 41(12):1775-81. PubMed ID: 16087330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.